[阿肌痛性侧面硬化症患者的息护理]
1International University of Health and Welfare, Office of Medical Education, Department of Neurology.
Brain and nerve = Shinkei kenkyu no shinpo
|November 11, 2024
概括
在日本,息护理主要为癌症患者提供服务,在肌缩侧面硬化症 (ALS) 方面的专家经验有限. 神经科医生和家庭护理医生需要为ALS症状管理提供息护理培训,特别是在阿片类药物使用方面.
科学领域:
- 医学专业 医学专业 医学专业
- 神经学 神经学
- 在瘤学瘤学.
背景情况:
- 在日本,息治疗主要是针对癌症的.
- 息护理专家通常缺乏对肌缩性侧面硬化症 (ALS) 的经验.
- 有效管理ALS症状对于患者的生活质量至关重要.
研究的目的:
- 突出需要改善日本ALS患者的息护理.
- 强调神经病学家,家庭护理医生和息治疗专家之间的合作的重要性.
- 解决ALS息治疗中的症状管理的具体挑战.
主要方法:
- 关于日本目前的息护理实践的文献综述.
- 分析癌症和ALS患者之间息护理需求的差异.
- 讨论阿片类药物使用在ALS生命终端护理中的作用.
主要成果:
- 日本的息护理专家对ALS息治疗没有足够的经验.
- 神经科医生和家庭护理医生需要对ALS缓和护理进行教育.
- 与癌症护理相比,ALS终身护理中的阿片类药物使用具有独特的考虑因素.
结论:
- 加强培训和合作对于为ALS患者提供适当的息护理至关重要.
- 息治疗方法必须根据ALS的特定症状概况进行调整.
- 医生在使用阿片类药物治疗ALS症状时必须谨慎并做出明智的判断.
相关概念视频
Continuing Care
1.4K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.4K
Cross-bridge Cycle
116.9K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
116.9K
Parkinson's Disease: Treatment
222
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
222
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165


